Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TTAX01

            Therapeutic Area: Podiatry Product Name: TTAX01

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 30, 2020


            Company's first biologic license application (BLA) candidate TTAX01 to enter Investigational New Drug (IND) Phase 3 Trials for Diabetic Foot Ulcer (DFU) indication as first biologic product to seek FDA approval for complex Wagner Grade 3 and 4 DFUs .